CLNN Clene Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1822791 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY-47.7%
TTM net income YoY20.4%
TTM EPS YoY—
Revenue 3-yr CAGR-22.1%
Net income 3-yr CAGR—
Margins
Gross margin79.5%
Operating margin-9,676.3%
Net margin-11,520.5%
FCF margin-6,240.1%
EBITDA margin-9,195.3%
Returns
ROE-1,738.4%
ROA-98.9%
ROIC (approx.)—
Asset turnover0.01x
Leverage & solvency
Liabilities / assets132.4%
Debt / equity—
Current ratio1.57x
Interest coverage-8.14x
Cash quality & payout
Operating cash flow / net income0.54x
Accruals ratio-45.4%
Payout ratio—
Capex / revenue4.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $56,000 | $90,000 | $15,000 | $77,000 | $15,000 | $27,000 | $81,000 | $91,000 |
| Cost of revenue | $16,000 | $36,000 | $0 | $23,000 | $0 | $0 | $20,000 | $18,000 |
| Gross profit | $40,000 | $54,000 | $15,000 | $54,000 | $15,000 | $27,000 | $61,000 | $73,000 |
| R&D expense | $4.45M | $3.47M | $329,000 | $5.50M | $3.51M | $3.51M | $1.48M | $5.57M |
| SG&A expense | $1.94M | $1.93M | $1.75M | $2.05M | $2.15M | $2.38M | $2.66M | $3.16M |
| Operating income | -$6.35M | -$5.35M | -$2.06M | -$7.50M | -$5.65M | -$5.86M | -$4.08M | -$8.65M |
| Interest expense | $665,000 | $695,000 | $791,000 | $746,000 | $649,000 | $679,000 | $608,000 | $516,000 |
| Pretax income | $3.92M | -$13.42M | -$8.09M | -$9.23M | -$8.78M | -$7.42M | -$751,000 | -$13.55M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | $3.92M | -$13.42M | -$8.09M | -$9.23M | -$8.78M | -$7.42M | -$751,000 | -$13.55M |
| EBITDA | -$6.00M | -$4.99M | -$1.71M | -$7.13M | -$5.28M | -$5.50M | -$3.67M | -$8.25M |
| EPS (basic) | 0.30 | -1.08 | -0.69 | — | -0.85 | -0.78 | -0.09 | — |
| EPS (diluted) | 0.05 | — | — | — | -0.85 | — | — | — |
| Weighted avg. shares (diluted) | 14.67M | — | — | — | 10.28M | — | — | — |
| Balance sheet | ||||||||
| Cash & equivalents | $9.89M | $9.67M | $5.94M | $5.19M | $7.98M | $7.34M | $9.89M | $12.15M |
| Short-term investments | — | — | — | — | — | — | — | $0 |
| Receivables | $43,000 | $43,000 | — | $0 | $0 | $0 | $0 | $64,000 |
| Inventory | $41,000 | $37,000 | $54,000 | $37,000 | $61,000 | $79,000 | $38,000 | $68,000 |
| Current assets | $14.49M | $14.91M | $13.02M | $8.98M | $12.67M | $11.98M | $14.67M | $16.16M |
| PP&E, net | $5.02M | $5.32M | $5.67M | $6.02M | $6.36M | $6.71M | $7.08M | $7.48M |
| Total assets | $22.16M | $23.04M | $21.66M | $18.13M | $22.31M | $22.12M | $25.31M | $27.34M |
| Current liabilities | $17.11M | $4.85M | $6.73M | $10.78M | $8.31M | $7.57M | $10.76M | $10.29M |
| Long-term debt | $17.51M | $17.60M | $17.70M | $17.79M | $17.88M | $16.46M | $16.63M | — |
| Total debt | $17.51M | $17.60M | $17.70M | $17.79M | $17.88M | $16.46M | $16.63M | — |
| Total liabilities | $36.97M | $47.82M | $40.47M | $35.72M | $34.67M | $30.68M | $30.29M | $36.19M |
| Shareholders' equity | -$14.81M | -$24.78M | -$18.81M | -$17.59M | -$12.36M | -$8.55M | -$4.97M | -$8.86M |
| Net debt | $7.62M | $7.93M | $11.76M | $12.60M | $9.89M | $9.12M | $6.74M | — |
| Shares outstanding | 14.21M | 12.78M | 11.78M | 10.85M | 10.22M | 9.46M | 8.67M | 8.09M |
| Cash flow statement | ||||||||
| Operating cash flow | -$4.62M | -$2.59M | -$4.53M | -$4.80M | -$3.99M | -$4.74M | -$5.01M | -$4.87M |
| Capital expenditure | $51,000 | — | — | $28,000 | $11,000 | $0 | $0 | $1,000 |
| Free cash flow | -$4.67M | — | — | -$4.83M | -$4.00M | -$4.74M | -$5.01M | -$4.87M |
| Investing cash flow | -$51,000 | -$1,000 | $0 | -$28,000 | -$11,000 | $0 | $0 | -$2,000 |
| Financing cash flow | $4.87M | $6.33M | $5.23M | $2.07M | $4.64M | $2.13M | $2.67M | $2.53M |
| Depreciation & amortization | $349,000 | $353,000 | $355,000 | $360,000 | $365,000 | $366,000 | $404,000 | $405,000 |
| Stock-based compensation | $1.08M | $1.04M | $1.31M | $1.36M | $1.70M | $1.37M | $1.95M | $1.80M |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.